Physician profile
Raquel Neeley
NPI 1972581296
$2,085.04
in general payments reported to CMS, 2019-2025
15 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $114 · 2021: $29.65 · 2022: $350 · 2023: $538 · 2024: $428 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $675.52 | 2022-2025 | Airsupra |
| Novo Nordisk INC | $262.11 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $256.12 | 2019-2023 | Arexvy |
| Abbvie INC. | $138.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.98 | 2021-2023 | |
| Abiomed | $99.06 | 2023 | Impella |
| Lilly USA, LLC | $97.72 | 2020-2024 | Mounjaro |
| Gilead Sciences, INC. | $90.85 | 2019 | |
| Boston Scientific Corporation | $82.94 | 2020 | |
| Integra Lifesciences Corporation | $78.71 | 2022 | |
| Alnylam Pharmaceuticals INC. | $68.14 | 2023-2025 | Givlaari |
| Idorsia Pharmaceuticals US INC | $50.41 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $22.96 | 2023 | |
| Exact Sciences Corporation | $15.18 | 2025 | The Cologuard Plus Collection Kit |
| Tactile Systems Technology INC | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Neeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.